Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley		Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene CAS Number: 80-56-8		Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
		Male Blood		
		Treatment Group (ppm)	
		50 °	100 ^a	
Cmax_p	red (ng/mL)	863 ± 92.1	7740 ± 2230	
Alpha (ł	nour ⁻¹)	1.06 ± 0.299	4.58 ± 1.35	
Alpha_H	lalf-life (hour)	0.656 ± 0.185	0.151 ± 0.0446	
Beta (ho	our ⁻¹)	0.0567 ± 0.0425	0.0541 ± 0.0965	
Beta_Ha	alf-life (hour)	12.2 ± 9.15	12.8 ± 22.9	
k10 (ho	ur⁻¹)	0.421 ± 0.130	1.75 ± 1.54	
k10_Ha	llf-life (hour)	1.65 ± 0.508	0.396 ± 0.349	
k12 (ho	ur⁻¹)	0.550 ± 0.235	2.74 ± 1.73	
k21 (ho	ur⁻¹)	0.143 ± 0.108	0.142 ± 0.187	
Cl1 (mL/	/h/kg)	34600 ± 9990	32100 ± 27100	
Cl2 (mL/	/h/kg)	45300 ± 17300	50300 ± 30000	
V1 (mL/	kg)	82300 ± 8790	18300 + 5290	
V2 (mL/	kg)	318000 ± 225000	356000 ± 557000	
Vss (mL,	/kg)	400000 ± 227000	374000 ± 557000	
AUC_0-	T (h*ng/mL)	2050 ± 592	4420 ± 3730	

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summa Compound/Analyte: Alpha-Pin CAS Number: 80-56-8	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene CAS Number: 80-56-8	
	Female Blood		
	Treatment Group (ppr	n)	
	50 °	100 ª	
Cmax_pred (ng/mL)	1340 ± 184	10800 ± 1940	
Alpha (hour ⁻¹)	0.987 ± 0.356	2.61 ± 0.623	
Alpha_Half-life (hour)	0.702 ± 0.253	0.266 ± 0.0634	
Beta (hour ⁻¹)	0.0399 ± 0.0378	0.0405 ± 0.0734	
Beta_Half-life (hour)	17.4 ± 16.5	17.1 ± 30.9	
k10 (hour ⁻¹)	0.311 ± 0.145	1.25 ± 0.899	
k10_Half-life (hour)	2.23 ± 1.04	0.552 ± 0.395	
k12 (hour ⁻¹)	0.590 ± 0.291	1.31 ± 0.955	
k21 (hour ⁻¹)	0.127 ± 0.114	0.0843 ± 0.119	
Cl1 (mL/h/kg)	17900 ± 7980	17600 ± 12300	
Cl2 (mL/h/kg)	34000 ± 14800	18400 ± 13000	
V1 (mL/kg)	57700 + 7950	14000 ± 2510	
V2 (mL/kg)	269000 + 222000	218000 ± 387000	
Vss (mL/kg)	326000 + 224000	232000 ± 388000	
AUC_0-T (h*ng/mL)	4300 ± 1910	8640 ± 6010	

Experiment Number: K03014	Τοχία	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene Oxide		Request Date: 10/27/2020 Request Time: 2:30:16
Route: Inhalation	Compound/Anal			
Species/Strain: Rat/Sprague-Dawley	C	CAS Number: 80-56-8		Lab: RTI
		Male Blood		
	T	reatment Group (ppm)	
		50 ^b	100 ^b	
	.)			
Cmax_obs (ng/n	nL)	173	220	
Tmax_obs (hour	·)	0.167	0.830	
Lambda_z (hour	1)	0.0488	0.0360	
Half-life (hour)		14.2	19.2	
AUCinf_pred (h'	*ng/mL)	1260	1820	

Experiment Number: K03014	periment Number: K03014Toxicokinetics Data Summarypute: InhalationCompound/Analyte: Alpha-Pinene/Alpha-Pinene oxiderecies/Strain: Rat/Sprague-DawleyCAS Number: 80-56-8		Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
Route: Inhalation			
Species/Strain: Rat/Sprague-Dawley			
	Female Blood		
	Treatment Group (ppm)		
	50 ^b	100 ^b	
(max_obs (ng/mL)	317	498	
Tmax_obs (hour)	0.167	0.167	
Lambda_z (hour-1)	0.0552	0.0600	
Half-life (hour)	12.6	11.6	
AUCinf_pred (h*ng/mL)	1200	1680	

Experiment Number: K03014 Route: Inhalation		Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pin	ene Oxide	Request Date: 10/27/2020 Request Time: 2:30:16
Species/Strain: Rat/Sprague-Daw	vley	CAS Number: 80-56-8		Lab: RTI
		Male Blood		
		Treatment Group (ppm)		
		50 °	100 °	
(Cmax pred (ng/mL)	181 ± 10.6	221 ± 11.4	
P	Alpha (hour ⁻¹)	1.17 ± 0.308	1.19 ±0.254	
P	Alpha_Half-life (hour)	0.593 ± 0.156	0.583 ±0.125	
E	Beta (hour⁻¹)	0.0637 ± 0.0107	0.0506 ± 0.0080)4
E	Beta_Half-life (hour)	10.9 ± 1.82	13.7 ± 2.17	
k	(10 (hour ⁻¹)	0.158 ± 0.0178	0.138 ± 0.0150	
k	<10_Half_life (hour)	4.38 ± 0.493	5.04 ±0.551	
k	(12 (hour ⁻¹)	0.604 ± 0.176	0.665 ± 0.154	
k	(21 (hour ⁻¹)	0.471 ± 0.146	0.438 ±0.111	
P	AUC 0-T (h*ng/mL)	1140 ± 106	1610 ± 149	

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetic Compound/Analyte: Alpl CAS Num	s Data Summary ha-Pinene/Alpha-Pinene Oxide nber: 80-56-8	Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
	Femal	le Blood	
	Treatmer	nt Group (ppm)	
		50 ° 100	0 °
Cmax pred (ng	;/mL) 321 ± 1	.6.9 534 ± 37.1	L
Alpha (hour ⁻¹)	1.11	± 0.210 1.01 ± 0	0.231
Alpha_Half-life	(hour) 0.62	5 ± 0.118 0.686 ±	0.157
Beta (hour-1)	0.08	23 ± 0.0195 0.0805	± 0.0305
Beta_Half-life (hour) 8.43	± 1.99 8.61 ±	3.26
k10 (hour-1)	0.30	0 ± 0.0350 0.352 ±	± 0.0583
k10_Half_life (l	hour) 2.31	± 0.270 1.97 ±	0.326
k12 (hour ⁻¹)	0.58	8 ± 0.132 0.508 ±	± 0.152
k21 (hour ⁻¹)	0.30	4 ± 0.0930 0.231 ±	± 0.101
AUC_0-T (h*ng	/mL) 1070 ± 1	.07 1520 ± 220)

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene CAS Number: 80-56-8	Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
	Male Mammary	
	Treatment Group (ppm)	
	50 ^d	100 ^d
Cmax_obs (ng/g)	73900	103000
Tmax_obs (hour)	0.250	0.500
Lambda_z (hour ⁻¹)	0.0431	0.0988
Half-life (hour)	16.1	7.02
Cl (g/h/kg)	138	125
AUCinf_pred (h*ng	g/g) 515000	1130000

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene CAS Number: 80-56-8		Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
	Female Mammary		
	Treatment Group (ppm)		
	50 ^d	100 ^d	
Cmax_obs (ng/g)	135000	245000	
Tmax_obs (hour)	0.500	0.500	
Lambda_z (hour ⁻¹)	0.0636	0.0329	
Half-life (hour)	10.9	21.1	
Cl (g/h/kg)	29.1	26.5	
AUCinf_pred (h*ng	g/g) 2650000	5740000	

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha- CAS Number: 80-56-8	Pinene Request Date: 10/27/2020 Lab: RTI
	Male Mammary (lipid adjuste	d)
	Treatment Group (ppm)	
	50 ^e	100 ^e
Cmax_obs (ng/g li	ipid) 663000	1300000
Tmax_obs (hour)	0.250	0.500
Lambda_z (hour ⁻¹) 0.0802	0.0915
Half-life (hour)	8.64	7.58
Cl (g/h/kg)	15.5	13.4
AUCinf_pred (h*n	ng/g) 4580000	10600000

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summa //Compound/Analyte: Alpha-Pinene CAS Number: 80-56-8	aryRequest Date: 10/27/2020Alpha-PineneRequest Time: 2:30:16Lab: RTI
	Female Mammary (lipid a	adjusted)
	Treatment Group (pp	m)
	50 °	100 ^e
Cmax_obs (ng/g li	ipid) 1180000	2530000
Tmax_obs (hour)	0.167	0.500
Lambda_z (hour ⁻¹) 0.0393	0.0285
Half-life (hour)	17.6	24.4
Cl (g/h/kg)	2.71	3.37
AUCinf_pred (h*n	ng/g) 28400000	45100000

Experiment Number: K03014	Toxicokinetics Data Summary	Request Date: 10/27/2020
Route: Inhalation	Compound/Analyte: Alpha-Pinene/Alpha-Pinene oxid	le Request Time: 2:30:16
Species/Strain: Rat/Sprague-Dawley	CAS Number: 80-56-8	Lab: RTI
	Male Mammary	
	Treatment Group (ppm)	
	50 ^f	100 ^f
(max, abc)(max)	6040	8020
	0940	8930
Tmax_obs (hour)	0.167	0.250
Lambda_z (hour ⁻¹)	0.0828	0.0633
Half-life (hour)	8.37	11.000
AUCinf_pred (h*n	g/g) 44200	63800

Experiment Number: K03014 Route: Inhalation Species/Strain: Rat/Sprague-Dawley	Toxicokinetics Data Summary Compound/Analyte: Alpha-Pinene/Alpha-Pinene oxide CAS Number: 80-56-8		Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI
	Female Mammar	У	
	Treatment Group (p	om)	
· · · · · · · · · · · · · · · · · · ·	50 ^f	100 ^f	
Cmax_obs (ng/g)	9310	14600	
Tmax_obs (hour)	0.0830	0.500	
Lambda_z (hour ⁻¹)	0.0402	0.0939	
Half-life (hour)	17.2	7.38	
AUCinf_pred (h*ng,	/g) 68100	123000	

Experiment Number: K03014	Toxicokinetics Data Summary	Request Date: 10/27/2020 Request Time: 2:30:16 Lab: RTI				
Route: Inhalation	Compound/Analyte: Alpha-Pinene/Alpha-Pinene oxide					
Species/Strain: Rat/Sprague-Dawley	CAS Number: 80-56-8					
Male Mammary (lipid adjusted)						
Treatment Group (ppm)						
	50 ^g	100 ^g				
Cmax obs (ng/g lipi	d) 34800	34800				
Tmax obs (hour)	0.0830	0.500				
Lambda_z (hour ⁻¹)	0.0855	0.0849				
Half-life (hour)	8.10	8.16				
AUCinf_pred (h*ng/	g) 178000	227000				

Experiment Number: K03014	Toxicokin	Toxicokinetics Data Summary		Request Date: 10/27/2020
Route: Inhalation	Compound/Analyte:	Compound/Analyte: Alpha-Pinene/Alpha-Pinene oxide		
Species/Strain: Rat/Sprague-Dawley	CAS	Number: 80-56-8		Lab: RTI
	Female M	ammary (lipid adju	sted)	
	Treat	ment Group (ppm)		
		50 ^g	100 ^g	
Cmax_obs (ng/g) 38	300	76600	
Tmax_obs (hour)	0.333	0.500	
Lambda_z (hour	⁻¹)	0.0778	0.0838	
Half-life (hour)		8.90	8.28	
AUCinf pred (h*	ng/g) 3220	00	491000	

LEGEND

MODELING METHOD & BEST FIT MODEL

- ^a Phoenix WinNonlin (Version 6.4), two-compartment
- ^b Phoenix WinNonlin (Version 6.4), noncompartmental, Because APO is a metabolite of AP, no parameters calculated from exposure (i.e., clearance, volume, Cmax/D, AUC/D) are reported. AUCinf_pred is actually the observed value.
- ^c Phoenix WinNonlin (Version 6.4), two-compartment, Because APO is a metabolite of AP, no parameters calculated from exposure (i.e., clearance, volume, Cmax/D, AUC/D) are reported.
- ^d Phoenix WinNonlin (Version 6.4), noncompartmental, Non-lipid adjusted data, concentration is expressed as ng/g mammary tissue
- ^e Phoenix WinNonlin (Version 6.4), noncompartmental, Concentration (ng/g) for lipid adjusted data is expressed as ng/g lipid in mammary tissue
- ^f Phoenix WinNonlin (Version 6.4), noncompartmental, Non-lipid adjusted data, concentration is expressed as ng/g mammary tissue. Because APO is a metabolite of AP, no parameters calculated from exposure (i.e., clearance, volume, Cmax/D, AUC/D) are reported.
- ^g Phoenix WinNonlin (Version 6.4), noncompartmental, Concentration (ng/g) for lipid adjusted data is expressed as ng/g lipid in mammary tissue. Because APO is a metabolite of AP, no parameters calculated from exposure (i.e., clearance, volume, Cmax/D, AUC/D) are reported.

ANALYTE

Alpha-Pinene, Alpha-Pinene oxide

TK PARAMETERS

- Cmax = Observed or Predicted Maximum plasma (or tissue) concentration
- Tmax = Time at which Cmax predicted or observed occurs
- Lambda_z = Non-compartmental analysis (NCA) terminal elimination rate constant, NCA ke or kelim
- Half_life = Lambda z Half_life, t 1/2, the terminal elimination half-life based on non-compartmental analysis

Alpha = Hybrid rate constant of the alpha phase

Alpha_Half-life = Half-life for the alpha phase

Beta = Hybrid rate constant of the beta phase

Beta_Half-life = Half-life for the beta phase

k10 = Elimination rate constant from the central compartment also ke or kelim

k10_Half-life = Half-life for the elimination process from the central compartment

k12 = Distribution rate constant from first to second compartment

k21 = Distribution rate constant from second to first compartment

Cl1 = Clearance of central compartment, Clapp or apparent clearance for intravenous groups

Cl2 = Clearance of the secondary compartment

V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution

NCA, Vapp apparent volume of distribution for intravenous studies

V2 = Volume of distribution for the peripheral compartment

Vss = Volume of distribution at steady state

AUC_0-T = Area under the plasma concentration versus time curve, AUC, from time ti (initial) to tf (final), AUClast

AUCinf = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

TK PARAMETERS PROTOCOL

Rat Blood and Mammary Tissue

50 ppm Rat Male, 50 ppm Rat Female, 100 ppm Rat Male, 100 ppm Rat Female

Male and female Harlan Sprague Dawley rats were exposed by whole body inhalation for 6 hours plus T90 per day for 7 consecutive days. Dose was calculated for individual animals and the average inhaled dose for the groups in mg/kg (71 and 142 mg/kg for male rats at 50 and 100 ppm, respectively; 77 and 152 mg/kg for female rats at 50 and 100 ppm, respectively). The mg/ kg doses are the estimated theoretical inhaled doses and not the doses absorbed from the respiratory tract. Both males and females were 69 days old at first exposure. Body weights ranged 256.2 to 281.8 g for males and 165.8 to 192.7 females at randomization. N = 39 animals/sex/group. Blood and mammary tissues were analyzed for alpha pinene and its metabolite alpha pinene oxide. Animals were fed irradiated NTP-2000 wafer feed available ad libitum, except during exposure. Water was available ad libitum. On Day 0, prior to the start of exposures, whole blood samples were collected from three rats per sex while the animals were under 70% CO2/30% O2 anesthesia via the orbital plexus to determine background levels of analyte. Animals were immediately returned to the exposure chamber to continue on study. Beginning on Day 6, whole blood samples were collected from three animals/sex/group via the retro-orbital plexus while under 70% CO2/30% O2 anesthesia at the following time points: pre-exposure (0 minutes) and post-exposure times of 5, 10, 15, 20, and 30 minutes, and 1, 2, 4, 8, 12, 24, and 48 hours. Following terminal blood collection, mammary glands were collected. All samples were stored at ultracold temperatures. Alpha pinene and alpha pinene and alpha pinene and mammary glands were determined using validated analytical methods. All variance listed for the parameters is standard error (± SE).